SI2303891T1 - Pirazolo kinazolini kot modulatorji aktivnosti protein kinaze - Google Patents

Pirazolo kinazolini kot modulatorji aktivnosti protein kinaze

Info

Publication number
SI2303891T1
SI2303891T1 SI200931429A SI200931429A SI2303891T1 SI 2303891 T1 SI2303891 T1 SI 2303891T1 SI 200931429 A SI200931429 A SI 200931429A SI 200931429 A SI200931429 A SI 200931429A SI 2303891 T1 SI2303891 T1 SI 2303891T1
Authority
SI
Slovenia
Prior art keywords
quinazolines
pyrazolo
protein kinase
kinase activity
activity modulators
Prior art date
Application number
SI200931429A
Other languages
English (en)
Inventor
Marina Caldarelli
Mauro Angiolini
Riccardo Colombo
Teresa Disingrini
Stefano Nuvoloni
Helena Posteri
Matteo Salsa
Marco Silvagni
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40887152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2303891(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of SI2303891T1 publication Critical patent/SI2303891T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
SI200931429A 2008-06-26 2009-06-17 Pirazolo kinazolini kot modulatorji aktivnosti protein kinaze SI2303891T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159114 2008-06-26
PCT/EP2009/057512 WO2009156315A1 (en) 2008-06-26 2009-06-17 Pyrazolo-quinazolines
EP09769164.6A EP2303891B1 (en) 2008-06-26 2009-06-17 Pyrazolo-quinazolines as protein kinase activity modulators

Publications (1)

Publication Number Publication Date
SI2303891T1 true SI2303891T1 (sl) 2016-06-30

Family

ID=40887152

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931429A SI2303891T1 (sl) 2008-06-26 2009-06-17 Pirazolo kinazolini kot modulatorji aktivnosti protein kinaze

Country Status (21)

Country Link
US (1) US8846701B2 (sl)
EP (1) EP2303891B1 (sl)
JP (1) JP5542133B2 (sl)
CN (1) CN102076689B (sl)
AR (2) AR072374A1 (sl)
AU (1) AU2009264431B2 (sl)
BR (1) BRPI0914649B1 (sl)
CA (1) CA2729436C (sl)
CL (1) CL2010001538A1 (sl)
CY (1) CY1117595T1 (sl)
DK (1) DK2303891T3 (sl)
EA (1) EA020703B9 (sl)
ES (1) ES2572360T3 (sl)
HK (1) HK1154383A1 (sl)
HR (1) HRP20160243T1 (sl)
HU (1) HUE027527T2 (sl)
MX (1) MX2010013843A (sl)
PL (1) PL2303891T3 (sl)
SI (1) SI2303891T1 (sl)
TW (1) TWI464172B (sl)
WO (1) WO2009156315A1 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2215091B1 (en) * 2007-12-04 2016-03-30 Nerviano Medical Sciences S.r.l. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
ES2552282T3 (es) 2009-03-27 2015-11-26 Nerviano Medical Sciences S.R.L. Derivados de N-aril-2-(2-arilaminopirimidin-4-il)pirrol-4-carboxamida como inhibidores de la cinasa MPS1
EP2598508B1 (en) 2010-07-30 2015-04-22 Nerviano Medical Sciences S.r.l. Isoxazolo-quinazolines as modulators of protein kinase activity
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
US8541576B2 (en) 2010-12-17 2013-09-24 Nerviano Medical Sciences Srl Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
JP5822944B2 (ja) * 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
WO2012098207A1 (en) * 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
JP5925808B2 (ja) * 2011-01-26 2016-05-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用
CN103339134B (zh) * 2011-01-26 2015-12-23 内尔维阿诺医学科学有限公司 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
JP5976778B2 (ja) * 2011-04-11 2016-08-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
JP6399660B2 (ja) * 2012-04-10 2018-10-03 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 癌治療用組成物および方法
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CN103130810B (zh) * 2013-03-11 2015-02-25 河南师范大学 一种吡唑并[1,5-c]喹唑啉类化合物的合成方法
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
UY37778A (es) * 2017-06-29 2019-01-31 Servier Lab NUEVA SAL DE N-(2,6-DIETILFENIL)-8-({4-[4-(DIMETILAMINO)PIPERIDIN-1-IL]-2- METOXIFENIL}AMINO)-1-METIL-4,5-DIHIDRO- 1H-PIRAZOLO[4,3-h]QUINAZOLINA-3- CARBOXAMIDA, SU PREPARACIÓN, Y LAS FORMULACIONES QUE LA CONTIENEN
WO2019002542A1 (en) 2017-06-30 2019-01-03 Les Laboratoires Servier COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
JP7178401B2 (ja) * 2017-07-11 2022-11-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのピラゾロキナゾリン誘導体
CN111094291B (zh) * 2017-08-11 2022-06-21 晟科药业（江苏）有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
CA3171979A1 (en) 2020-03-27 2021-09-30 Josep Bassaganya-Riera Plxdc2 ligands
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
CN114685520B (zh) * 2020-12-25 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022143576A1 (zh) * 2020-12-31 2022-07-07 恒元生物医药科技(苏州)有限公司 一种吡唑并喹唑啉类化合物、其制备方法及应用
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
AU2003225580A1 (en) * 2002-02-19 2003-09-09 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
CN1826343A (zh) * 2003-05-22 2006-08-30 法玛西雅意大利公司 吡唑并－喹唑啉衍生物、它们的制备方法和它们作为激酶抑制剂的用途
PL2125822T3 (pl) 2006-12-21 2015-04-30 Nerviano Medical Sciences Srl Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz

Also Published As

Publication number Publication date
EA020703B9 (ru) 2015-12-30
HUE027527T2 (en) 2016-10-28
AR113818A2 (es) 2020-06-17
BRPI0914649A2 (pt) 2015-07-07
CN102076689B (zh) 2014-10-15
EP2303891A1 (en) 2011-04-06
BRPI0914649B1 (pt) 2021-07-06
EP2303891B1 (en) 2016-02-17
MX2010013843A (es) 2011-01-21
WO2009156315A1 (en) 2009-12-30
CN102076689A (zh) 2011-05-25
ES2572360T3 (es) 2016-05-31
HRP20160243T1 (hr) 2016-04-08
US8846701B2 (en) 2014-09-30
TWI464172B (zh) 2014-12-11
CA2729436C (en) 2016-08-09
PL2303891T3 (pl) 2016-08-31
US20110105542A1 (en) 2011-05-05
AU2009264431A2 (en) 2011-02-17
AR072374A1 (es) 2010-08-25
CY1117595T1 (el) 2017-04-26
EA020703B1 (ru) 2015-01-30
HK1154383A1 (en) 2012-04-20
JP2011525516A (ja) 2011-09-22
EA201170090A1 (ru) 2011-08-30
AU2009264431A1 (en) 2009-12-30
AU2009264431B2 (en) 2013-11-07
CL2010001538A1 (es) 2012-02-03
TW201004960A (en) 2010-02-01
DK2303891T3 (en) 2016-05-30
CA2729436A1 (en) 2009-12-30
JP5542133B2 (ja) 2014-07-09

Similar Documents

Publication Publication Date Title
PL2303891T3 (pl) Pirazolo-chinazoliny jako modulatory aktywności kinaz białkowych
HUS1900014I1 (hu) Proteinkináz inhibitorok
EP2259678A4 (en) PROTEIN KINASE MODULATORS
ZA201005245B (en) Protein expression systems
ZA201203849B (en) Novel kinase modulators
ZA201006033B (en) Microencapsulation
ZA201201627B (en) Compounds as tyrosine kinase modulators
HRP20170959T1 (hr) Farmaceutska suspenzija
EP2306836A4 (en) MODULATORS OF BMI-1 PROTEIN EXPRESSION
PL2145914T3 (pl) Preparaty plastyfikatorów
PL2329032T3 (pl) Sposoby wykorzystujące polipeptydy o aktywności hydrolazy
GB0823326D0 (en) Self-calibration
IL210069A0 (en) Protein kinase inhibitors
PL2625176T3 (pl) Podstawione związki 6-amino-pirydazyn-3-ylo-karboksyamidu jako modulatory kinazy białkowej
GB2462761B (en) Protein formulation
GB2466379B (en) Protein stabilizer
GB0816976D0 (en) Protein
GB0817507D0 (en) Protein cages
TWI373184B (en) Control center
GB0813253D0 (en) Protein expression system
GB2462726B (en) Protein expression
GB0818627D0 (en) Protein
GB0810567D0 (en) Protein expression
GB0811893D0 (en) Protein expression
GB0817077D0 (en) Proteins